The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,298,586 in first-year total cost, median $1,864,846.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-J (J2)]5
Most frequent institutions
- APPLIKATE TECHNOLOGIES, INC.1
- ARIMA GENOMICS, INC.1
- CIVATECH ONCOLOGY, INC.1
- TWINSTRAND BIOSCIENCES, INC.1
- VOXIMETRY, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with driver-negative tumors2R44CA247185-03A1 | SELVARAJ, SIDDARTH | ARIMA GENOMICS, INC., CA | $2,069,712 | ZCA1 |
| 2023 | One-click Automated 3D Treatment Planning for Radiopharmaceutical Therapy2R44CA221491-04 | GRUDZINSKI, JOSEPHWICKRE, PAUL | VOXIMETRY, INC., WI | $2,000,000 | ZCA1 |
| 2023 | Commercializing CivaSheet for Pancreatic Cancer Patients2R44CA210770-04A1 | PEREZ, KRISTY | CIVATECH ONCOLOGY, INC., NC | $1,864,846 | ZCA1 |
| 2023 | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing2R44CA233381-05A1 | BICKEL, KELLIEHOURIGAN, CHRISTOPHER S | TWINSTRAND BIOSCIENCES, INC., WA | $1,139,103 | ZCA1 |
| 2023 | Commercial Readiness for Direct-to-Digital Pathology2R44CA189522-04A1 | LEVENE, MICHAEL JOHNTORRES, RICHARD | APPLIKATE TECHNOLOGIES, INC., CT | $224,925 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.